News
APLS
48.72
+2.27%
1.08
Weekly Report: what happened at APLS last week (0415-0419)?
Weekly Report · 1d ago
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Seeking Alpha · 4d ago
Insiders Could Have Profited By Holding onto Apellis Pharmaceuticals Shares Despite 15% Drop
Apellis Pharmaceuticals, Inc. Insiders sold US$7.9m in stock over the last year. The average selling price of US$60.47 is lower than the current share price. In the last three months the company saw significant insider selling at US$4.8m. Apellis pharmaceuticals insiders didn't buy any shares in the last 12 months. The company boasts a high insider ownership of 3.6% of the company. But the stock price has dropped 15% in the past week.
Simply Wall St · 5d ago
Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanks · 5d ago
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanks · 6d ago
Relative Strength Alert For Apellis Pharmaceuticals
NASDAQ · 6d ago
Apellis Pharmaceuticals Price Target Cut to $57.00/Share From $67.00 by Wedbush
Dow Jones · 6d ago
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Dow Jones · 6d ago
Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57
Benzinga · 6d ago
Commit To Purchase Apellis Pharmaceuticals At $35, Earn 13.1% Using Options
NASDAQ · 04/16 17:07
Expert Ratings For Apellis Pharmaceuticals
Apellis Pharmaceuticals (NASDAQ:APLS) has an average price target of $79.43. The 12-month price targets, analyzed by analysts, offer insights into the company's valuation. Apellis pharmaceuticals is a biopharmaceutical company focused on the complement system. 14 analysts have expressed a variety of opinions on the company over the past quarter.
Benzinga · 04/15 14:00
Apellis Pharmaceuticals Price Target Maintained With a $92.00/Share by HC Wainwright & Co.
Dow Jones · 04/15 11:17
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Benzinga · 04/15 11:07
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
TipRanks · 04/15 10:20
Weekly Report: what happened at APLS last week (0408-0412)?
Weekly Report · 04/15 09:20
Apellis Pharmaceuticals Hold Rating: Navigating Syfovre’s Mixed Reception and Emerging Competition
TipRanks · 04/10 06:19
Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)
TipRanks · 04/09 10:40
Weekly Report: what happened at APLS last week (0401-0405)?
Weekly Report · 04/08 09:21
Ocugen advances Phase 1/2 trial for eye disease candidate
Ocugen advances Phase 1/2 trial for gene therapy candidate OCU410 for eye disorder geographic atrophy. The one-time therapy is expected to rival FDA-approved GA drugs such as Syfovre and Izervay. Ocugen shares traded higher on Friday.
Seeking Alpha · 04/05 14:56
APELLIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/04 20:05
More
Webull provides a variety of real-time APLS stock news. You can receive the latest news about Apellis Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.